

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

Sr. No.	Particulars	Quarter Ended			Year Ended	
		June 30, 2018	March 31, 2018	June 30, 2017	March 31, 2018	
		(Unaudited)	(Audited)*	(Unaudited)	(Audited)	
I	Revenue from operations	853.93	781.56	713.42	3219.21	
II	Other Income	13.63	12.58	5.72	39.54	
III	Total Income (I+II)	867.56	794.14	719.14	3258.75	
IV	Expenses					
	a) Cost of materials consumed	253.27	223.54	253.34	923.20	
	b) Purchases of stock-in-trade	35.68	43.08	27.62	168.30	
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(11.23)	(10.63)	(13.35)	20.98	
	d) Employee benefits expense	195.40	168.56	174.66	712.78	
	e) Finance costs	4.93	6.45	5.58	24.02	
	f) Depreciation and amortisation expense	44.49	43.15	43.34	174.36	
	g) Other expenses	266.80	248.31	249.17	952.31	
	Total Expenses (IV)	789.34	722.46	740.36	2975.95	
V	Profit before exceptional items and tax (III-IV)	78.22	71.68	(21.22)	282.80	
VI	Exceptional items	-	-	-	-	
VII	Profit before tax (V-VI)	78.22	71.68	(21.22)	282.80	
VIII	Tax Expense					
	Current tax	16.29	14.73	-	60.01	
	Short / (Excess) provision of earlier years	(0.68)	(0.34)	-	(0.34)	
	Deferred tax liability / (asset)	(2.91)	5.98	(0.97)	(9.98)	
IX	Profit for the period from continuing operations (VII-VIII)	65.52	51.31	(20.25)	233.11	
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss -					
	Actuarial gain/(loss)	2.84	2.03	0.27	2.30	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.61)	(0.49)	-	(0.49)	
	B (i) Items that will be reclassified to profit or loss					
	-Exchange difference in translating the financial statement of foreign operation	(0.15)	0.15	(0.04)	(0.10)	
	-Gain/(loss) on cash flow hedge	0.53	0.95	2.38	(0.14)	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	
	Other Comprehensive Income	2.61	2.64	2.61	1.57	
XI	Total comprehensive Income for the period (IX+X)	68.13	53.95	(17.64)	234.68	
XII	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.24	25.24	25.24	
XIII	Other Equity				2669.71	
XIV	Earnings per share (of ₹ 2/- each) (Not annualised):					
	Basic (₹)	5.19	4.07	(1.60)	18.47	
	Diluted (₹)	5.19	4.07	(1.60)	18.47	



**SIGNED FOR IDENTIFICATION
BY**

G. M. Kapadia

**G. M. KAPADIA & CO.
MUMBAI.**

Notes:

- 1 The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 9, 2018.
- 2 The Auditors of the Company have carried out the limited review of the above unaudited financial results.
- 3 Effective April 1, 2018, the Company has adopted Ind AS 115 on 'Revenue from Contracts with Customers' using the cumulative catch-up transition method. The adoption of this standard did not have any material impact on the above financial results.
- 4 Revenue from Operations for the quarter ended June 30, 2018 and March 31, 2018 are shown net of Goods and Service Tax (GST). Net Sales for the corresponding quarter is shown inclusive of excise duty and for the financial year ended March 31, 2018 includes excise duty upto June 30, 2017. For comparison purposes revenue excluding excise duty is given below:

Sr.No.	Particulars	Quarter Ended			(₹ Crores)
		June 30, 2018 (Unaudited)	March 31, 2018 (Audited)*	June 30, 2017 (Unaudited)	Year Ended March 31, 2018 (Audited)
A.	Total Income from operations	853.93	781.56	713.42	3219.21
B.	Excise Duty on sales (included in other expenses)	-	-	10.28	10.28
C.	Total Income from operations excluding Excise duty on Sales (A-B)	853.93	781.56	703.14	3208.93

- 5 The Board of Directors have allotted 153000 fully paid - up equity shares of ₹ 2/- each @ ₹ 300/- per share on May 29, 2018 upon exercise of options granted under Ipca Laboratories Ltd. Employees Stock Option Scheme - 2014.
- 6 *The figures of quarter ended March 31, 2018 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2018 and figures upto the third quarter ended December 31, 2017 which were subjected to Limited Review by the Statutory Auditors.
- 7 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 8 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,
Date : August 9, 2018

SIGNED FOR IDENTIFICATION
BY
G.M. Kapadia
G. M. KAPADIA & CO.
MUMBAI.



By Order of the Board
For Ipca Laboratories Limited

Premchand Godha
Premchand Godha
Chairman & Managing Director
(DIN 00012691)

PRESS RELEASE

Ipca Laboratories Q1 FY19 Unaudited Financial Results

Mumbai, August 9, 2018: Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended June 30, 2018 of the financial year 2018-19.

Key Financials of Q1 FY19

- Net Total Income up 21% at Rs. 867.56 crores.
- Indian formulations income up 36% at Rs. 400.94 crores.
- Exports Income up 3% at Rs. 381.73 crores.
- EBIDTA margin @ 17.57% in Q1 FY19 as against @ 3.25% in Q1 FY18.

Q1 FY19 at a glance			(Rs. Crores)
Particulars	Q1 FY19	Q1 FY18	Growth
Net Total Income	867.56	719.14	21%
Export Income	381.73	371.12	3%
EBITDA before Forex (gain)/Loss	152.42	23.37	552%
Forex (gain) / loss	24.78	(4.33)	-
Finance Cost	4.93	5.58	(12%)
Depreciation and Amortisation	44.49	43.34	3%
Tax Expense	12.70	(0.97)	
Net Profit / (Loss) after tax	65.52	(20.25)	-
Earnings per share of Rs. 2/- each (Rs.)	5.19	(1.60)	-

Q1 FY19 Revenue break-up			(Rs. Crores)
Particulars	Q1 FY19	Q1 FY18	Growth
Formulations			
Domestic	400.94	295.00	36%
Exports			
Branded Generics	78.50	78.99	-
Institutional	41.48	34.89	19%
Generics	104.02	121.98	(15%)
Total Formulations	624.94	530.86	18%
APIs			
Domestic	60.02	36.21	66%
Exports	157.73	135.26	17%
Total APIs	217.75	171.47	27%
Grand Total	842.69	702.33	20%




Ipca Laboratories Ltd.
www.ipca.com

25, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6954
E: ipca@ipca.com CIN: L24239MH1949PLC007837

: 2 :

About Ipca Laboratories:

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports which now account for 44% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



Premchand Godha
Chairman & Managing Director

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22-6210 6050

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6954
E: ipca@ipca.com CIN: L24239MH1949PLC007837